UK CRO RxCelerate sets up first US office in Boston

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/LewisTsePuiLung)
(Image: Getty/LewisTsePuiLung)

Related tags: CRO, RxCelerate, Drug discovery, Drug development

RxCelerate is opening its first office in the US to be closer to clients and meet a "huge demand" for drug discovery and development services in the greater Boston area.

Cambridge, UK-headquartered RxCelerate is a contract research organization (CRO) providing a range of services, including medicinal chemistry, antibody discovery, preclinical safety and efficacy testing.

“With our home in Europe’s largest bioscience cluster, establishing a base in the epicenter of American biotech seemed to be the logical next step. We already have a number of US clients, but this new move brings us right to their doorstep,”​ said Jill Reckless, CEO of RxCelerate, in a press release.

The new office is located on the Babraham Research Campus in Cambridge, MA.

As part of the move, the company has hired Laura Hamilton to head US operations. Hamilton joined RxCelerate from the Massachusetts Biotechnology Council (MassBio).

“There is huge demand for drug discovery and development services in the greater Boston area, and I look forward to introducing many more companies to the unique RxCelerate approach. I am certain RxCelerate can be as successful in Cambridge, MA, as they have been in Cambridge, UK,”​ said Hamilton.

RxCelerate has been working with the Department for International Trade (DIT) over the last two years as it looked to expand abroad and develop its international trade strategy, according to the company.

RxCelerate has not responded to a request for comment.

Related news

Show more

Related products

show more

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Related suppliers

Follow us


View more